Our Focus
The West Virginia Chapter of the National Bleeding Disorders Foundation, WVNBDF, provides education, support, awareness, and advocacy for the bleeding disorder community.
We are the leading resource for West Virginians affected by bleeding disorders. You can count on us to ensure your voice is heard. It’s with your help that we can make a difference. Learn more and get involved.
Our Mission ... Into Action
-
We provide mission-focused experiences through education, support, community connections, and fun for those affected by bleeding disorders.
-
We provide year-round events and fundraisers to spread awareness, educate, and generate crucial resources in support of our mission. Hope to see you at our next event!
-
AdvocacyWe fight to protect access to quality healthcare and treatments we need to live healthy lives, but we can't do it without your voice. Discover how you and your family can make a big difference by joining our advocacy efforts.
News Articles
The U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application for VONVENDI®, which expands its indication to include prophylaxis use to reduce the frequency of bleeding episodes in adults with von Willebrand disease (VWD), including those with type 1 and 2 disease, and for on-demand and perioperative management of bleeding in pediatric patients with VWD.
Federal:
2025 Bleeding Disorders Conference
NBDF wrapped up another successful Bleeding Disorders Conference. The policy team was busy with sessions on blood and product safety, access to insurance, and sharing updates on what’s happening in Washington, DC. This year there was also a session dedicated to NBDF’s advocacy efforts focused on women and girls. You can see the highlights from this year’s conference here.
Pathway to Cures, NBDF’s venture philanthropy fund, is an investor in Be Biopharma, Inc., a clinical-stage company developing engineered B cell medicines. Be Biopharma recently announced the first participant treated with their therapy BE-101 in the BeCoMe-9 Phase 1/2 clinical trial.
What is BE-101?
Advertisement
Click to learn more.
